C. David James

About C. David James

C. David James, With an exceptional h-index of 103 and a recent h-index of 58 (since 2020), a distinguished researcher at North Western University, specializes in the field of cancer research, cancer biology, brain tumors, neuro-oncology, mouse models.

His recent articles reflect a diverse array of research interests and contributions to the field:

ARF4-mediated retrograde trafficking as a driver of chemoresistance in GBM

Cancer-associated fibroblast–secreted collagen is associated with immune inhibitor receptor LAIR1 in gliomas

The immune system and metabolic products in epilepsy and glioma-associated epilepsy: emerging therapeutic directions

Immune Spatial Differences Between Short and Long-term Surviving Glioblastoma Patients

Abstract LB335: Establishment of the effective dose of the STAT3 inhibitor WP1066 used in combination with STING activation for reprograming the preclinical glioma microenvironment

Docetaxel targets aggressive methylation profiles and serves as a radiosensitizer in high-risk meningiomas

Metixene is an incomplete autophagy inducer in preclinical models of metastatic cancer and brain metastases

Kunitz-type protease inhibitor TFPI2 remodels stemness and immunosuppressive tumor microenvironment in glioblastoma

C. David James Information

University

Position

Professor Emeritus of Neurological Surgery Feinberg School of Medicine

Citations(all)

43745

Citations(since 2020)

14125

Cited By

35263

hIndex(all)

103

hIndex(since 2020)

58

i10Index(all)

246

i10Index(since 2020)

186

Email

University Profile Page

Google Scholar

C. David James Skills & Research Interests

cancer research

cancer biology

brain tumors

neuro-oncology

mouse models

Top articles of C. David James

ARF4-mediated retrograde trafficking as a driver of chemoresistance in GBM

Neuro-Oncology

2024/3/20

Cancer-associated fibroblast–secreted collagen is associated with immune inhibitor receptor LAIR1 in gliomas

Journal of Clinical Investigation

2024/2/15

The immune system and metabolic products in epilepsy and glioma-associated epilepsy: emerging therapeutic directions

2024/1/1

Immune Spatial Differences Between Short and Long-term Surviving Glioblastoma Patients

The Journal of Immunology

2023/5/1

Abstract LB335: Establishment of the effective dose of the STAT3 inhibitor WP1066 used in combination with STING activation for reprograming the preclinical glioma microenvironment

Cancer Research

2023/4/14

Docetaxel targets aggressive methylation profiles and serves as a radiosensitizer in high-risk meningiomas

Neuro-oncology

2023/3/1

Metixene is an incomplete autophagy inducer in preclinical models of metastatic cancer and brain metastases

The Journal of clinical investigation

2023/12/15

Kunitz-type protease inhibitor TFPI2 remodels stemness and immunosuppressive tumor microenvironment in glioblastoma

Nature Immunology

2023/10

WDR82-Mediated H3K4me3 Is Associated with Tumor Proliferation and Therapeutic Efficacy in Pediatric High-Grade Gliomas

Cancers

2023/6/30

IMMU-10. PILOCYTIC ASTROCYTOMAS SHOW EVIDENCE OF INTRINSIC IMMUNE SURVEILLANCE AND ACTIVATION WITHIN THE TUMOR MICROENVIRONMENT

Neuro-Oncology

2023/6/1

Ribonucleotide reductase regulatory subunit M2 drives glioblastoma TMZ resistance through modulation of dNTP production

Science Advances

2023/5/17

Cell-directed aptamer therapeutic targeting for cancers including those within the central nervous system

Oncoimmunology

2022/12/31

Identification and characterization of a novel indoleamine 2, 3-dioxygenase 1 protein degrader for glioblastoma

Journal of Medicinal Chemistry

2022/11/21

Modeling therapy-driven evolution of glioblastoma with patient-derived xenografts

Cancers

2022/11/9

CDK 4/6 Inhibitors are Potent Radiosensitizers in Retinoblastoma Protein Positive Meningiomas

International Journal of Radiation Oncology, Biology, Physics

2022/11/1

SLFN11 Negatively Regulates Noncanonical NFκB Signaling to Promote Glioblastoma Progression

Cancer research communications

2022/9/13

Regulation of TORC1 by MAPK Signaling Determines Sensitivity and Acquired Resistance to Trametinib in Pediatric BRAFV600E Brain Tumor Models

Clinical Cancer Research

2022/9/1

Myeloid Cell Classification and Therapeutic Opportunities Within the Glioblastoma Tumor Microenvironment in the Single Cell-Omics Era

2022/6/16

DNMT targeting enhances vulnerability of glioblastoma cells to MNK inhibition

Cancer Research

2022/6/15

The central nervous system immune cell interactome is a function of cancer lineage, tumor microenvironment and STAT3 expression

Cancer Research

2022/6/15

See List of Professors in C. David James University(North Western University)

Co-Authors

academic-engine